focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 18th Nov 2013 08:10

AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation.APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation.Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation.Aveva: Panmure Gordon ups target price from 2374p to 2386p and keeps a hold recommendation.Bank of Georgia: Panmure Gordon raises target price from 2200p to 3000p and retains a buy recommendation.Big Yellow Group: Numis raises target price from 460p to 535p keeping an add rating.Cairn Energy: UBS moves target price from 310p to 305p and stays with its buy recommendation.Cape: JP Morgan lowers target price from 299p to 288p and maintains a neutral rating.Carr's Milling: Investec increases target price from 1710p to 1900p and maintains a buy recommendation.Diploma: Jefferies takes target price from 720p to 750p and reiterates a buy recommendation. Numis downgrades from add to hold with a target price of 697p.Drax Group: Liberum Capital raises target price from 640p to 735p upgrading to buy.Euromoney: Investec ups target price from 1200p to 1250p and reiterates a buy recommendation.Foxtons: Canaccord Genuity upgrades to buy woth a target price of 320p.Gem Diamonds: JP Morgan moves target price from 180p to 185p retaining an overweight rating.International Consolidated Airlines Group: Nomura takes target price from 335p to 380p and keeps a buy recommendation.ITE Group: Investec places its target price (prev.: 335p) under review, while keeping its buy recommendation.Lancashire Holdings: Numis raises target price from 865p to 935p and upgrades from hold to add.Lonmin: Investec ups target price from 266p to 287p, but still recommends selling.Majestic Wine: Investec raises target price from 495p to 620p and retains a buy recommendation. Panmure Gordon increases target price from 500p to 635p and stays with its buy recommendation.MITIE Group: Investec ups target price from 310p to 330p and keeps a buy recommendation.New World Resources: Jefferies shifts target price from 70p to 75p and maintains its hold recommendation.Northern Petroleum: Westhouse Securities shifts target price from 123p to 120p, while upgrading to buy.Ocean Wilson Holdings: Cantor Fitzgerald ups target price from 1345p to 1400p and stays with its buy recommendation.Ophir Energy: Canaccord Genuity ups target price from 375p to 400p and retains a hold recommendation.Partnership Assurance: Deutsche Bank reduces target price from 470p to 385p keeping a hold recommendation.SAB Miller: JP Morgan increases target price from 3270p to 3465p and leaves its overweight rating unchanged.Shire: Jefferies raises target price from 3100p to 3400p and keeps a buy recommendation.Summit Corporation: N+1 Singer moves target price from 11p to 16.3p and reiterates a buy recommendation.Ultra Electronics: UBS cuts target price from 1900p to 1820p maintaining a neutral rating. JP Morgan reduces target price from 2100p to 1920p leaving its neutral rating unaltered.Vedanta Resources: Deutsche Bank cuts target price from 1050p to 1020p retaining a hold recommendation. Credit Suisse reduces target price from 1350p to 1270p and leaves its outperform rating unaltered.Volex Group: FinnCap upgrades to hold with a target price of 90p.
More News
27 Mar 2019 15:56

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

Read more
2 Jan 2019 14:08

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

Read more
17 Dec 2018 09:14

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

Read more
11 Dec 2018 16:34

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

Read more
11 Dec 2018 14:31

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

Read more
6 Sep 2018 13:55

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

Read more
16 Aug 2018 13:53

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

Read more
20 Apr 2018 13:11

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

Read more
19 Apr 2018 15:07

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
27 Mar 2018 12:18

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

Read more
14 Mar 2018 17:52

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

Read more
1 Feb 2017 16:50

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

Read more
1 Feb 2017 12:15

Summit Therapeutics Details Phase III Programme For Ridinilazole

Read more
18 Jan 2017 12:09

Summit Therapeutics Appoints David Roblin As Chief Operating Officer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.